ARCHIVES

BMS Execs Knew Of Flaws In ImClone Plan For C225 Prior To $2-Billion Licensing Deal

This article is from The Cancer Letter archive.

Vol. 28 No. 25 | June 21, 2002

Download PDF Visit The Full Archive

Related Articles

FDA Approves Xeloda For Breast Cancer After Failure Of Anthracycline Treatment.

September 28, 2001

Zometa Prevents Bone Loss In Premenopausal Women

August 29, 2008

Copeland Named Director, UF Cancer Center

February 10, 1995

Abbott PCR Test For HCV Load Sensitive to Within 12 IU/mL

May 27, 2011

FDA’s Jane Henney

February 11, 1994

NCAB Says Restrictions on Animal Research Threatens Progress

May 20, 1988